

1. Clark MS, Jansen KL, Cloy JA. Treatment of Childhood and Adolescent Depression [Internet]. Vol. 86, American Family Physician. 2012 Sep [cited 2021 Apr 28]. Available from: <http://familydoctor.org/641.xml>
2. Hazell P, O'Connell D, Heathcote D, Robertson J, Henry D. Efficacy of tricyclic drugs in treating child and adolescent depression: a meta-analysis. *BMJ* (1995) 310:897–901. doi: 10.1136/bmj.310.6984.897
3. Keller MB, Ryan ND, Strober M, Klein RG, Kutcher SP, Birmaher B, et al. Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. *J Am Acad Child Adolesc Psychiatry* (2001) 40:762–72. doi: 10.1097/00004583-200107000-00010
4. Wagner KD, Ambrosini P, Rynn M, Wohlberg C, Yang R, Greenbaum MS, et al. Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials. *JAMA* (2003) 290:1033–41. doi: 10.1001/jama.290.8.1033
5. Emslie GJ, Rush J, Weinberg WA, Kowatch RA, Hughes CW, Carmody T, et al. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. *Arch Gen Psychiatry* (1997) 54:1031–7. doi: 10.1001/archpsyc.1997.01830230069010
6. Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E. Selective serotonin reuptake inhibitors in childhood depression: Systematic review of published versus unpublished data. *Lancet* (2004) 363:1341–5. doi: 10.1016/S0140-6736(04)16043-1
7. Spielmans GI, Spence-Sing T, Parry P. Duty to Warn: Antidepressant Black Box Suicidality Warning Is Empirically Justified. *Front Psychiatry* [Internet]. 2020 Feb 13 [cited 2021 Apr 26];11:1. Available from: <https://www.frontiersin.org/article/10.3389/fpsy.2020.00018/full>
8. Leslie LK, Newman TB, Chesney PJ, Perrin JM. The food and drug administration's deliberations on antidepressant use in pediatric patients. *Pediatrics* (2005) 116:195–204. doi: 10.1542/peds.2005-0074
9. Hammad TA. Relationship between psychotropic drugs and pediatric suicidality. Silver Spring, MD: Food and Drug Administration (2004). Available at: <https://www.dropbox.com/s/gto5w4qcumk9hic/2004%20FDA%20Hammad.pdf?dl=0> [Accessed April 22nd 2021]
10. March JS, Silva S, Petrycki S, Curry J, Wells K, Fairbank J, Burns B, Domino M, McNulty S, Vitiello B, Severe J. The Treatment for Adolescents With Depression Study (TADS): long-term effectiveness and safety outcomes. *Arch Gen Psychiatry*. 2007 Oct;64(10):1132–43. doi: 10.1001/archpsyc.64.10.1132. Erratum in: *Arch Gen Psychiatry*. 2008 Jan;65(1):101. PMID: 17909125
11. Vitiello B, Silva SG, Rohde P, Kratochvil CJ, Kennard BD, Reinecke MA, et al. Suicidal events in the Treatment for Adolescents With Depression Study (TADS). *J Clin Psychiatry* (2009) 70:741–7. doi: 10.4088/JCP.08m04607
12. Bridge JA, Iyengar S, Salary CB, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. *JAMA* 2007; 297:1683.
13. Hetrick SE, McKenzie JE, Cox GR, et al. Newer generation antidepressants for depressive disorders in children and adolescents. *Cochrane Database Syst Rev* 2012; 11:CD004851.
14. Cipriani A, Zhou X, Del Giovane C, et al. Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis. *Lancet* 2016; 388:881.
15. Gibbons RD, Brown CH, Hur K, Marcus SM, Bhaumik DK, Erkens JA, et al. Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents. *Am J Psychiatry* (2007) 164:1356–63. doi: 10.1176/appi.ajp.2007.07030454
16. Gibbons RD, Brown CH, Hur K, Davis JM, Mann JJ. Suicidal thoughts and behavior with

antidepressant treatment: reanalysis of the randomized placebo-controlled studies of fluoxetine and venlafaxine. *Arch Gen Psychiatry* (2012) 69:580–7. doi: 10.1001/archgenpsychiatry.2011.2048

17. Sparks JA, Duncan BL. Outside the black box: re-assessing pediatric antidepressant prescription. *J Can Acad Child Adolesc Psychiatry* (2013) 22:240
18. Apter A, Lipschitz A, Fong R, Carpenter DJ, Krulewicz S, Davies JT, et al. Evaluation of suicidal thoughts and behaviors in children and adolescents taking paroxetine. *J Child Adolesc Psychopharmacol* (2006) 16:77–90. doi: 10.1089/cap.2006.16.77
19. Khan A, Khan S, Kolts R, Brown WA. Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports. *Am J Psychiatry* 2003; 160:790.
20. Ignaszewski MJ, Waslick B. Update on Randomized Placebo-Controlled Trials in the Past Decade for Treatment of Major Depressive Disorder in Child and Adolescent Patients: A Systematic Review. *J Child Adolesc Psychopharmacol* 2018; 28:668.
21. Brent DA. Antidepressants and Suicidality. *Psychiatr Clin North Am*. 2016 Sep;39(3):503-12. doi: 10.1016/j.psc.2016.04.002. Epub 2016 Jun 24. PMID: 27514302.
22. Safer DJ, Zito JM. Treatment-emergent adverse events from selective serotonin reuptake inhibitors by age group: children versus adolescents. *J Child Adolesc Psychopharmacol* (2006) 16:159–69. doi: 10.1089/cap.2006.16.159.
23. Pompili M, Tondo L, Baldessarini RJ. Suicidal risk emerging during antidepressant treatment: recognition and intervention. *Clin Neuropsychiatry* (2005) 2:66–72.
24. KoKoAung E, Cavenett S, McArthur A, Aromataris E. The association between suicidality and treatment with selective serotonin reuptake inhibitors in older people with major depression: a systematic review. *JBI Database System Rev Implement Rep*. 2015 Apr 17;13(3):174-205. doi: 10.11124/jbisrir-2015-2272. PMID: 26447056.
25. Olfson M, Marcus SC, Shaffer D. Antidepressant drug therapy and suicide in severely depressed children and adults: A case-control study. *Arch Gen Psychiatry* (2006) 63:865–72. doi: 10.1001/archpsyc.63.8.865